PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$42.63|
|52 Week High||US$36.38|
|52 Week Low||US$70.82|
|1 Month Change||12.72%|
|3 Month Change||-4.50%|
|1 Year Change||-9.72%|
|3 Year Change||-5.56%|
|5 Year Change||265.61%|
|Change since IPO||158.52%|
Recent News & Updates
Estimating The Intrinsic Value Of PTC Therapeutics, Inc. (NASDAQ:PTCT)
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of PTC Therapeutics, Inc...
|PTCT||US Biotechs||US Market|
Return vs Industry: PTCT underperformed the US Biotechs industry which returned 25.7% over the past year.
Return vs Market: PTCT underperformed the US Market which returned 33.6% over the past year.
Stable Share Price: PTCT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: PTCT's weekly volatility (5%) has been stable over the past year.
About the Company
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, including rare diseases and oncology. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of SMA in adults and children two months and older in Brazil.
Is Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: PTCT ($42.63) is trading above our estimate of fair value ($39.42)
Significantly Below Fair Value: PTCT is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: PTCT is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: PTCT is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PTCT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PTCT is overvalued based on its PB Ratio (15.3x) compared to the US Biotechs industry average (3.2x).
How is Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PTCT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: PTCT is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: PTCT's is expected to become profitable in the next 3 years.
Revenue vs Market: PTCT's revenue (20.1% per year) is forecast to grow faster than the US market (9.7% per year).
High Growth Revenue: PTCT's revenue (20.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PTCT's Return on Equity is forecast to be very high in 3 years time (205.7%).
How has Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PTCT is currently unprofitable.
Growing Profit Margin: PTCT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PTCT is unprofitable, and losses have increased over the past 5 years at a rate of 32.8% per year.
Accelerating Growth: Unable to compare PTCT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PTCT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: PTCT has a negative Return on Equity (-198.93%), as it is currently unprofitable.
How is Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: PTCT's short term assets ($1.1B) exceed its short term liabilities ($291.0M).
Long Term Liabilities: PTCT's short term assets ($1.1B) do not cover its long term liabilities ($1.6B).
Debt to Equity History and Analysis
Debt Level: PTCT's debt to equity ratio (219%) is considered high.
Reducing Debt: PTCT's debt to equity ratio has increased from 57.4% to 219% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PTCT has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if PTCT has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PTCT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PTCT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PTCT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PTCT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PTCT's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Stuart Peltz (61 yo)
Dr. Stuart W. Peltz, Ph D., co-founded PTC Therapeutics Inc. in 1998 and has been its Chief Executive Officer since 1998. Dr. Peltz has been Independent Director of Health Sciences Acquisitions Corporation...
CEO Compensation Analysis
Compensation vs Market: Stuart's total compensation ($USD10.55M) is above average for companies of similar size in the US market ($USD5.28M).
Compensation vs Earnings: Stuart's compensation has increased whilst the company is unprofitable.
Experienced Management: PTCT's management team is considered experienced (2.8 years average tenure).
Experienced Board: PTCT's board of directors are seasoned and experienced ( 15.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: PTCT insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.3%.
PTC Therapeutics, Inc.'s employee growth, exchange listings and data sources
- Name: PTC Therapeutics, Inc.
- Ticker: PTCT
- Exchange: NasdaqGS
- Founded: 1998
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$3.010b
- Shares outstanding: 70.60m
- Website: https://www.ptcbio.com
Number of Employees
- PTC Therapeutics, Inc.
- 100 Corporate Court
- South Plainfield
- New Jersey
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/18 00:49|
|End of Day Share Price||2021/09/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.